Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

Completed

Conditions studied: Melanoma

In brief

This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.

Key facts

Study ID

NCT03438279

Run by

Bristol-Myers Squibb

People needed

600

Starts

2015-06-23

Expected to finish

2017-12-28

Last updated by the study team

2018-02-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of melanoma

You may not qualify if…

• Age less than 18 years old

Where it is running

• Local Institution — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.